Supplementary Table S1 Events within 30 days and restart of anticoagulation

	Safety population ($N = 352$)
Thrombotic event within 30 days	
Patients with thromboembolic event,[a] No. (%)	34 (9.7)
Deep vein thrombosis	13 (3.7)
Ischemic stroke	13 (3.7)
Myocardial infarction	7 (2.0)
Pulmonary embolism	5 (1.4)
Stroke, uncertain of classification	1 (0.3)
TIA	1 (0.3)
Days to first thromboembolic event, median (IQR)	10.0 (2.0–18.0)
Restart of full oral anticoagulation	
Patients with full oral anticoagulation, No. (%)	100 (28.4)
Days to full oral anticoagulation, median (IQR)	10.0 (5.0–16.0)
Patients with first thromboembolic event before restart,[b] No. (%)	8 (2.3)
Patients with first thromboembolic event after restart, No. (%)	0 (0.0)
Hemorrhagic events within 30 days	
Patients with hemorrhagic events, No. (%)	29 (8.2)
Days to first hemorrhagic events, median (IQR)	3.0 (1.0–8.0)
Patients with hemorrhagic events after day 3, No. (%)	15 (4.3)
Days to first hemorrhagic events after day 3, median (IQR)	9.0 (5.0–17.0)
Composite of thromboembolic event and hemorrhagic event	
Patients with composite of thromboembolic and hemorrhagic events,[c] No. (%)	48 (13.6)
Death within 30 days	
Mortality, No. (%)	49 (13.9)
Days to death, median (IQR)	12.0 (8.0–18.0)

Abbreviations: IQR, interquartile range; TIA, transient ischemic attack.
[a]Some patients had >1 thrombotic event.
[b]Thrombotic events that occurred on the day of restarting anticoagulation were considered to have occurred before the restart.
[c]Hemorrhagic events within the first 3 days were excluded.

Supplementary Table S2 Frequency of Oral Anticoagulant Drug

Oral anticoagulant	No. (%) ($n = 100$)
Apixaban 10.0 mg	1 (1.0)
Apixaban 2.5 mg	19 (19.0)
Apixaban 5.0 mg	28 (28.0)
Dabigatran 110.0 mg	2 (2.0)
Dabigatran 150.0 mg	2 (2.0)
Edoxaban 30.0 mg	2 (2.0)
Phenprocoumon 3.0 mg	1 (1.0)
Rivaroxaban 10.0 mg	1 (1.0)
Rivaroxaban 15.0 mg	7 (7.0)
Rivaroxaban 20.0 mg	21 (21.0)
Warfarin with a dose range 2.0–7.5 mg	16 (16.0)

Note: Percentages are based on total number of patients who have taken an oral anticoagulant within 30 days as the denominator. For patients with multiple oral anticoagulant records, only the first oral anticoagulant is considered.

Supplementary Table S3 List of oral anticoagulant drugs taken within 30 days

Patient ID	Bolus date	Oral anticoagulant generic name	Dose, mg	Total no. of doses	Frequency of dose	Non-restart of therapeutic-dose due to renal and\or liver dysfunction	Date of firstoral anticoagulant	Day of first oral anticoagulant (from bolus date)
8004	16–11–29	Apixaban	2.5	–		–	16–11–30	2
11004	16–10–22	Apixaban	5	35		–	16–10–23	2
400003	16–02–15	Apixaban	2.5	–		–	16–02–16	2
3004	16–02–11	Rivaroxaban	20	2		–	16–02–12	2
100002	16–05–08	Rivaroxaban	20	32		–	16–05–09	2
24025	18–05–21	Apixaban	5	–	BID	No	18–05–23	3
35004	16–05–16	Apixaban	2.5	1		–	16–05–18	3
229001	18–02–25	Apixaban	5	–	BID	No	18–02–27	3
400006	16–04–22	Apixaban	2.5	3		–	16–04–24	3
4004	16–02–17	Rivaroxaban	20	32		–	16–02–19	3
46009	18–04–09	Rivaroxaban	15	–	QD	No	18–04–11	3
301002	16–07–22	Rivaroxaban	20	1		–	16–07–24	3
14013	18–04–04	Apixaban	5	–	BID	No	18–04–07	4
210004	18–02–19	Apixaban	2.5	–	BID	No	18–02–22	4
7001	15–09–26	Rivaroxaban	20	29		–	15–09–29	4
46008	18–03–05	Rivaroxaban	20	–	QD	No	18–03–08	4
51002	16–05–08	Rivaroxaban	20	–		–	16–05–11	4
210002	17–12–15	Rivaroxaban	20	–	PM	No	17–12–18	4
3008	16–05–13	Apixaban	5	57		–	16–05–17	5
3026	18–05–01	Apixaban	5	–	BID	No	18–05–05	5
242003	18–04–27	Apixaban	5	–	QD	No	18–05–01	5
301010	17–12–02	Apixaban	2.5	62		–	17–12–06	5
400019	18–01–09	Apixaban	5	–	QD	No	18–01–13	5
29007	16–12–12	Edoxaban	30	11		–	16–12–16	5
16003	15–12–26	Rivaroxaban	20	23		–	15–12–30	5
100003	17–03–14	Rivaroxaban	15	1		–	17–03–18	5
154006	17–09–04	Rivaroxaban	20	–	QD	No	17–09–08	5
210001	17–10–17	Rivaroxaban	15	–	QD	No	17–10–21	5
26004	16–08–29	Warfarin	5	3		–	16–09–02	5
41006	16–04–16	Warfarin	5	3		–	16–04–20	5
210003	18–01–04	Apixaban	5	–	BID	No	18–01–09	6
400007	16–05–29	Apixaban	5	14		–	16–06–03	6
24010	16–05–11	Rivaroxaban	20	29		–	16–05–16	6
154005	17–06–16	Rivaroxaban	20	17		–	17–06–21	6
301008	17–09–02	Rivaroxaban	20	26		–	17–09–07	6
14014	18–04–18	Apixaban	5	–	BID	No	18–04–24	7
153007	18–03–21	Apixaban	5	–	BID	No	18–03–27	7
153008	18–04–10	Edoxaban	30	–	QD	No	18–04–16	7
12003	16–05–11	Apixaban	2.5	2		–	16–05–18	8
13008	16–03–09	Apixaban	2.5	11		–	16–03–16	8
38003	16–02–23	Rivaroxaban	20	28		–	16–03–01	8
242002	18–03–19	Rivaroxaban	20	–	QD	No	18–03–26	8
301005	17–07–26	Rivaroxaban	15	6		–	17–08–02	8
13013	17–02–20	Apixaban	5	48		–	17–02–28	9

Supplementary Table S3 (*Continued*)

Patient ID	Bolus date	Oral anticoagulant generic name	Dose, mg	Total no. of doses	Frequency of dose	Non-restart of therapeutic-dose due to renal and\or liver dysfunction	Date of firstoral anticoagulant	Day of first oral anticoagulant (from bolus date)
301001	16–07–17	Apixaban	2.5	60		–	16–07–25	9
206002	17–07–13	Dabigatran	110	–	BID	No	17–07–21	9
14005	16–06–16	Warfarin	5	–		–	16–06–24	9
4003	16–02–15	Apixaban	5	10		–	16–02–24	10
13012	17–01–30	Apixaban	5	29		–	17–02–08	10
14011	17–12–21	Apixaban	5	–	BID	No	17–12–30	10
400001	16–01–31	Apixaban	2.5	42		–	16–02–09	10
210006	18–04–08	Phenprocoumon	3	–	QD	No	18–04–17	10
41009	16–08–02	Warfarin	5	4		–	16–08–11	10
46003	16–02–16	Apixaban	2.5	22		–	16–02–26	11
49006	18–04–18	Apixaban	5	–	BID	No	18–04–28	11
400008	16–06–23	Apixaban	5	46		–	16–07–03	11
41008	16–07–08	Rivaroxaban	20	20		–	16–07–18	11
221007	18–02–20	Rivaroxaban	15	–	QD	No	18–03–02	11
11003	16–02–07	Warfarin	2.5	1		–	16–02–17	11
26003	16–06–16	Apixaban	5	47		–	16–06–27	12
14009	17–09–07	Rivaroxaban	10	–	QD	No	17–09–18	12
154001	16–06–22	Apixaban	5	11		–	16–07–04	13
221005	18–02–04	Dabigatran	110	–	BID	No	18–02–16	13
153005	17–11–23	Apixaban	2.5	–	BID	No	17–12–06	14
400018	17–12–27	Apixaban	2.5	–	BID	No	18–01–09	14
301003	17–02–22	Dabigatran	150	2		–	17–03–07	14
46005	16–11–17	Rivaroxaban	15	24		–	16–11–30	14
29004	15–11–18	Warfarin	5	23		–	15–12–01	14
51004	16–12–05	Apixaban	5	36		–	16–12–19	15
1001	15–06–10	Warfarin	3	34		–	15–06–24	15
33005	16–08–24	Warfarin	2.5	–		–	16–09–07	15
11012	18–02–26	Apixaban	2.5	–	BID	No	18–03–13	16
13004	15–12–28	Apixaban	2.5	30		–	16–01–12	16
207007	18–02–12	Apixaban	5	–	BID	No	18–02–27	16
29001	15–11–02	Warfarin	5	8		–	15–11–17	16
49004	16–10–19	Warfarin	5	20		–	16–11–03	16
3002	15–12–15	Apixaban	2.5	27		–	15–12–31	17
13018	17–12–18	Apixaban	5	–	BID	No	18–01–04	18
33006	17–05–05	Apixaban	5	–	BID	No	17–05–22	18
18001	15–08–15	Warfarin	5	9		–	15–09–01	18
24013	16–06–18	Apixaban	5	1		–	16–07–06	19
51003	16–07–08	Rivaroxaban	20	16		–	16–07–27	20
301004	17–04–21	Rivaroxaban	20	1		–	17–05–10	20
38004	16–06–08	Warfarin	4	17		–	16–06–27	20
241002	18–05–10	Dabigatran	150	–	BID	No	18–05–30	21
24001	15–07–07	Rivaroxaban	20	29		–	15–07–27	21
152003	18–04–20	Rivaroxaban	20	–	QD	No	18–05–10	21
46010	18–06–01	Warfarin	2.5	–	QD	No	18–06–21	21

(*Continued*)

Supplementary Table S3 (*Continued*)

Patient ID	Bolus date	Oral anticoagulant generic name	Dose, mg	Total no. of doses	Frequency of dose	Non-restart of therapeutic-dose due to renal and\or liver dysfunction	Date of firstoral anticoagulant	Day of first oral anticoagulant (from bolus date)
3023	18–03–02	Apixaban	5	–	BID	No	18–03–23	22
13017	17–12–17	Apixaban	5	–	BID	No	18–01–07	22
101003	16–07–03	Apixaban	2.5	21		–	16–07–24	22
24011	16–05–11	Apixaban	5	14		–	16–06–02	23
24014	16–09–21	Apixaban	5	27		–	16–10–14	24
352002	17–12–17	Apixaban	2.5	–	BID	No	18–01–09	24
259001	17–08–30	Rivaroxaban	15	–	QD	No	17–09–23	25
13002	15–07–20	Warfarin	2	20		–	15–08–13	25
29006	16–04–15	Warfarin	5	10		–	16–05–09	25
14012	18–02–18	Apixaban	2.5	–	BID	No	18–03–19	30
152001	16–05–17	Rivaroxaban	20	1		–	16–06–15	30
18006	16–04–20	Warfarin	5	8		–	16–05–19	30

Abbreviations: BID, twice a day; PM, post meridiem; QD, once a day.
Note: For patients with multiple oral anticoagulant records, only the first oral anticoagulant is considered.

Supplementary Table S4 Outcome up to day 30 for restarted and non-restarted overall[a]—safety population

Outcome	Not restarted on full OAC	Restarted on full OAC	HR (CI)[b]	*p*-Value
Number of subjects	252	100		
Hemorrhage, *n* (%)	11 (4.4%)	4 (4.0%)	0.84 (0.27–2.65)	0.770
TE, *n* (%)	26 (10.3%)	8 (8.0%)	0.72 (0.33–1.60)	0.427
Death, *n* (%)	46 (18.3%)	3 (3.0%)	0.15 (0.05–0.48)	$<$0.001
Composite of hemorrhage, death, and TE, *n* (%)	84 (24.7%)	2 (16.7%)	0.61 (0.15–2.50)	0.492

Abbreviations: CI, confidence interval; HR, hazard ratio; OAC, oral anticoagulant; TE, thromboembolic event.
Note: *p*-Values are calculated using a log-rank test.
[a]The restart group refers to the group of subjects who have restarted AC during the follow-up period from day 1 to day 30.
[b]HR(CI) values are calculated using a Cox proportional hazards regression model, with restart group as the predictor variable. Program name: outcome.sas; Produced: 09JUL20.

Supplementary Table S5 Univariate comparison of anticoagulation restart versus non-restart using day 14 as the landmark

Outcome	OAC non-restart, No. (%) ($N = 234$)	OAC restart, No. (%) ($N = 67$)	HR (CI)[a]	*p*-Value[b]
Hemorrhage	2 (0.9)	3 (4.5)	5.38 (1.08–26.90)	0.039
Thromboembolic event	12 (5.1)	0 (0.0)	0.27 (0.07–1.05)	0.060
Death	17 (7.3)	3 (4.5)	0.61 (0.19–1.95)	0.429
Composite of hemorrhage, death, and thromboembolic event	29 (12.4)	6 (9.0)	0.73 (0.31–1.70)	0.474

Abbreviations: CI, confidence interval; HR, hazard ratio; OAC, oral anticoagulant.
[a]HR was calculated using a Cox proportional hazards regression model, with restart group as the predictor variable. The CI was constructed by inverting the partial-likelihood score test under the Cox model. For the test of thromboembolic event, in which a quasi-complete separation feature presented, Peto's estimation of the HR (CI) based on the log-rank test was used.
[b]*p*-values were calculated using a log-rank test.

